Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S, Okamoto M, Kaieda S, Fujimoto K, Nagata S, Tominaga M, Nakamura M, Zaizen Y, Nouno T, Koga T, Kawayama T, Kuwana M, Ida H, Hoshino T. Sakamoto S, et al. Among authors: kuwana m. Respir Investig. 2018 Nov;56(6):464-472. doi: 10.1016/j.resinv.2018.07.007. Epub 2018 Aug 24. Respir Investig. 2018. PMID: 30150008
Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N, Okamoto M, Kaieda S, Fujimoto K, Ebata T, Tajiri M, Nakamura M, Tominaga M, Wakasugi D, Kawayama T, Kuwana M, Mimori T, Ida H, Hoshino T. Yoshida N, et al. Among authors: kuwana m. Respir Investig. 2017 Jan;55(1):24-32. doi: 10.1016/j.resinv.2016.08.007. Epub 2016 Sep 30. Respir Investig. 2017. PMID: 28012490
Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis.
Horai Y, Koga T, Fujikawa K, Takatani A, Nishino A, Nakashima Y, Suzuki T, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Ida H, Kakugawa T, Sakamoto N, Ishimatsu Y, Mukae H, Hamaguchi Y, Fujimoto M, Kuwana M, Origuchi T, Kohno S, Kawakami A. Horai Y, et al. Among authors: kuwana m. Mod Rheumatol. 2015 Jan;25(1):85-9. doi: 10.3109/14397595.2014.900843. Epub 2014 Apr 9. Mod Rheumatol. 2015. PMID: 24716595
Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
Kaieda S, Gono T, Masui K, Nishina N, Sato S, Kuwana M; A Multicenter Retrospective Cohort of Japanese Patients with Myositis-associated ILD (JAMI) investigators. Kaieda S, et al. Among authors: kuwana m. PLoS One. 2020 Jun 11;15(6):e0234523. doi: 10.1371/journal.pone.0234523. eCollection 2020. PLoS One. 2020. PMID: 32525903 Free PMC article.
Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial.
Azuma A, Chung L, Behera D, Chung M, Kondoh Y, Ogura T, Okamoto M, Swarnakar R, Zeng X, Zou H, Meng X, Gahlemann M, Alves M, Kuwana M; SENSCIS trial investigators. Azuma A, et al. Among authors: kuwana m. Respir Investig. 2021 Mar;59(2):252-259. doi: 10.1016/j.resinv.2020.10.005. Epub 2020 Nov 19. Respir Investig. 2021. PMID: 33223487 Free article. Clinical Trial.
2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease.
Kondoh Y, Makino S, Ogura T, Suda T, Tomioka H, Amano H, Anraku M, Enomoto N, Fujii T, Fujisawa T, Gono T, Harigai M, Ichiyasu H, Inoue Y, Johkoh T, Kameda H, Kataoka K, Katsumata Y, Kawaguchi Y, Kawakami A, Kitamura H, Kitamura N, Koga T, Kurasawa K, Nakamura Y, Nakashima R, Nishioka Y, Nishiyama O, Okamoto M, Sakai F, Sakamoto S, Sato S, Shimizu T, Takayanagi N, Takei R, Takemura T, Takeuchi T, Toyoda Y, Yamada H, Yamakawa H, Yamano Y, Yamasaki Y, Kuwana M; joint committee of Japanese Respiratory Society and Japan College of Rheumatology. Kondoh Y, et al. Among authors: kuwana m. Respir Investig. 2021 Nov;59(6):709-740. doi: 10.1016/j.resinv.2021.04.011. Epub 2021 Oct 1. Respir Investig. 2021. PMID: 34602377 Review.
Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.
Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T. Inoue Y, et al. Among authors: kuwana m. Respir Med. 2021 Oct;187:106574. doi: 10.1016/j.rmed.2021.106574. Epub 2021 Aug 12. Respir Med. 2021. PMID: 34564020 Free article. Clinical Trial.
Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, Masuda I, Tochimoto A, Baba S, Okamoto Y, Ota Y, Yamanaka H. Gono T, et al. Among authors: kuwana m. Rheumatology (Oxford). 2010 Sep;49(9):1713-9. doi: 10.1093/rheumatology/keq149. Epub 2010 May 23. Rheumatology (Oxford). 2010. PMID: 20498012
554 results